新质生产力赋能生物制造 天美生物与中国长城资产战略签约

Core Viewpoint - The seminar focused on leveraging new productive forces to anchor high-quality development in biomanufacturing, highlighting the integration of financial capital and technology enterprises [1] Group 1: Company Practices - Xi'an Tianmei Biotechnology Co., Ltd. showcased its technological accumulation and industrial advantages in natural ingredient biomanufacturing, emphasizing its commitment to high-value innovation and sustainable production [2] - The company aims to respond to national innovation-driven development strategies by optimizing production processes and reducing resource consumption and environmental impact [2] Group 2: Financial Empowerment - China Great Wall Asset Management Co., Ltd. emphasized its leading position in mergers and acquisitions within the industry, focusing on high-tech and health sectors, aligning with national biomanufacturing financial support policies [3] - The company plans to provide comprehensive support to Tianmei Biotechnology, including financing for technology research and development and industry chain integration [3] Group 3: Strategic Guidance - Zhang Yuzhong, former deputy director of the Ministry of Commerce's Investment Promotion Bureau, highlighted the dual opportunities and challenges in China's pharmaceutical foreign trade and the importance of biomanufacturing in national development strategies [4] - He suggested organizing large-scale events in the biomanufacturing sector to promote advanced technologies and products [4] Group 4: Expert Insights - Tian Huimin, a researcher, identified biomanufacturing as a key sector for new productive forces, emphasizing its role in alleviating resource and environmental pressures and enhancing global manufacturing competitiveness [5] - The biopharmaceutical manufacturing industry has maintained over 15% growth, indicating significant potential for developing new productive forces [5] Group 5: Think Tank Support - The establishment of a research base for traditional Chinese medicine and biomanufacturing aims to facilitate deep integration of industry, academia, and research, providing policy consulting and resource allocation support [6] - This initiative aligns with national efforts to enhance biomanufacturing capabilities [6] Group 6: Collaborative Efforts - Experts from various organizations discussed the importance of biomanufacturing in capital markets and the need for a standardized industry framework [7] - The collaboration between technology, finance, and think tanks is seen as a practical example of empowering industry [7] Group 7: Strategic Signing - A strategic cooperation agreement was signed between Xi'an Tianmei Biotechnology and China Great Wall Asset Management, focusing on integrating technological and financial resources for high-quality development in biomanufacturing [8][9] - This partnership is expected to drive technological innovation and financial support in key strategic industries, contributing to national health and manufacturing strategies [9]